Cna Financial Corp Allakos Inc. Transaction History

Cna Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$8.55 - $111.89 $54,121 - $708,263	-6,330 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$76.53 - $110.43 $68,111 - $98,282	890 Added 16.36%	6,330 $670,000
Q2 2021 Aug 12, 2021	BUY	$85.37 - $114.1 $29,879 - $39,935	350 Added 6.88%	5,440 $464,000
Q4 2020 Feb 12, 2021	SELL	$79.58 - $152.45 $38,198 - $73,176	-480 Reduced 8.62%	5,090 $713,000
Q3 2020 Nov 12, 2020	BUY	$66.43 - $90.99 $60,451 - $82,800	910 Added 19.53%	5,570 $454,000
Q2 2020 Aug 13, 2020	BUY	$44.04 - $80.69 $205,226 - $376,015	4,660 New	4,660 $335,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.